Covixyl TM has a component that stops the virus from attaching to nasal tissue, decreasing the viral load in the tissue milieu. The nasal spray catches, inactivates, and assists in killing the virus as it takes root and matures in the nasal passages, reducing the possibility of infection. CovixylTM has successfully completed human clinical studies, confirming the in vitro and in vivo research conducted by Salvacion USA Inc. We collaborated with the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), and were chosen to receive a Cascade Assay grant from the NCI in June 2021 for CovixylTM nasal spray.